Related Experiment Video
Updated: Aug 31, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies
Binsah S George1, Binoy Yohannan1, Anneliese Gonzalez1
1Department of Hematology/Oncology, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin Street, MSB 5.216, Houston, TX 77030, USA.
Abstract:
Mixed-phenotype acute leukemia (MPAL) comprises a heterogenous group of leukemias that are genetically, immunophenotypically, and clinically, diverse. Given the rarity of the disease, the diagnosis and treatment of MPAL is extremely challenging. Recent collaborative efforts have made significant progress in understanding the complex genomic landscape of MPAL. Some retrospective studies support starting ALL-type induction followed by an allogeneic stem cell transplant(allo-sct) in the first complete remission; however, due to the inherent bias of retrospective data and small case series, a prospective validation of AML- and ALL-based regimen, and the incorporation of targeted therapies based on genetics and immunophenotype are warranted. The prognosis of adults and children with MPAL varies; this justifies modulating the intensity of therapy, including the use of allo-sct as a consolidation strategy.
Insights
Mixed-phenotype acute leukemia (MPAL) is a rare and diverse blood cancer. Further research is needed for better diagnosis and treatment strategies, including targeted therapies and stem cell transplants.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Mixed-phenotype acute leukemia (MPAL) presents significant diagnostic and therapeutic challenges due to its heterogeneity.
- Understanding the genetic landscape of MPAL is crucial for improving patient outcomes.
Purpose of the Study:
- To review current understanding of MPAL's genomic landscape.
- To highlight the need for prospective validation of treatment strategies and targeted therapies.
Main Methods:
- Review of recent collaborative efforts and retrospective studies on MPAL.
- Analysis of genomic and immunophenotypic data.
Main Results:
- MPAL is genetically, immunophenotypically, and clinically diverse.
- Retrospective data suggest ALL-type induction followed by allogeneic stem cell transplant (allo-sct) in first complete remission.
Conclusions:
- Prospective validation of AML- and ALL-based regimens is warranted.
- Incorporation of targeted therapies based on MPAL genetics and immunophenotype is essential.
- Therapy intensity should be modulated, potentially including allo-sct, based on individual prognosis.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...